TY - T1的随机对照试验的阿托伐他汀在轻度至中度阿尔茨海默病JF -神经学乔-神经病学SP - 956 LP - 964 - 10.1212 / WNL。首页0 b013e3181d6476a六世- 74 - 12盟——h·h·费尔德曼盟——r·s·杜迪AU - m . Kivipelto AU - d . l .火花盟- d d水域AU - r·w·琼斯AU - e . Schwam AU - r·辛德勒AU - j . Hey-Hadavi AU - d . a . DeMicco盟- a . Breazna A2 - Y1 - 2010/03/23 UR - //www.ez-admanager.com/content/74/12/956.abstract N2 -背景:首页有证据表明,他汀类药物可能有保护和症状在阿尔茨海默病(AD)中获益。LEADe研究是一个随机对照试验(RCT)评估患者的阿托伐他汀的疗效和安全性轻度至中度的广告。方法:这是一个国际多中心、双盲、随机、与这些相应平行的组织学习。受试者轻度至中度可能广告这边是细微精神状态检查(分数),50 - 90岁,每日服用多奈哌齐10毫克≥3个月前筛选。进入低密度脂蛋白胆固醇(低密度脂蛋白)在95年和& lt; 195 mg / dL。病人被随机分为阿托伐他汀80毫克/天或72周,后跟一个双盲安慰剂,8周阿托伐他汀撤军阶段。Coprimary端点被认知的变化(阿尔茨海默氏症评估Scale-Cognitive内部氧化物[ADAS-Cog])和全局函数(阿尔茨海默病临床合作研究全球的印象变化[ADCS-CGIC])在72周。结果:共有640名患者被随机分配在书房里。没有明显差异的coprimary端点ADAS-cog ADCS-CGIC或二级端点。 Atorvastatin was generally well-tolerated. Conclusions: In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. This treatment was generally well-tolerated without unexpected adverse events. Classification of evidence: This study provides Class II evidence that intensive lipid lowering with atorvastatin 80 mg/day in patients with mild to moderate probable Alzheimer disease (aged 50–90), taking donepezil, with low-density lipoprotein cholesterol levels between 95 and 195 mg/dL over 72 weeks does not benefit cognition (as measured by Alzheimer's Disease Assessment Scale-Cognitive Subscale) (p = 0.26) or global function (as measured by Alzheimer's Disease Cooperative Study Clinical Global Impression of Change) (p = 0.73) compared with placebo. AchEI=acetylcholinesterase inhibitor; AD=Alzheimer disease; ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; ADCS-CGIC=Alzheimer's Disease Cooperative Study Clinical Global Impression of Change; ADFACS=Alzheimer's Disease Functional Assessment and Change Scale; ANCOVA=analysis of covariance; APP=amyloid precursor protein; BSI=boundary shift integral; CDR-SB=Clinical Dementia Rating-Sum of Boxes; LDL-C=low-density lipoprotein cholesterol; LOCF=last observation carried forward; LS=least-squares; MITT=modified intent-to-treat population; MMSE=Mini-Mental State Examination; NPI=Neuropsychiatric Inventory; RCT=randomized controlled trial; SAE=serious adverse event. ER -